Choroidal Melanoma

Choroidal melanoma grows from pigment‑making (melanocyte) cells in the choroid—the carpet‑like sheet of blood vessels that feeds the retina at the back of the eyeball.
Ciliary‑body melanoma sprouts from the same kind of cells, but they sit in the ciliary body—a ring of muscle and gland tissue just behind the iris that helps the eye focus and makes aqueous fluid. Together these cancers make up most “uveal” or “intra‑ocular” melanomas. They are rare (about six new cases per million people a year) yet serious because they can slip into the bloodstream and seed the liver or lungs.Mayo Clinic

Choroidal and ciliary‑body melanomas are the two most common forms of uveal (intra‑ocular) melanoma, a rare but aggressive eye cancer that arises from pigment‑making melanocytes in the vascular uveal tract. Together they account for almost 95 % of primary eye melanomas, with the choroid (the light‑absorbing layer behind the retina) involved in ~85 % of cases and the ciliary body (the ring‑shaped muscle that focuses the lens) in ~10 %–12 %.⁠ Early growth is usually silent, so many tumours are detected only when they threaten sight or have already seeded the liver via the bloodstream.⁠EyeWikiNCBI

Melanoma starts when the DNA inside a melanocyte changes (mutates). The faulty instructions let the cell divide too fast and live too long, so a lump (tumor) forms and can eventually break loose (metastasis).Mayo Clinic

The uvea (iris + ciliary body + choroid) is dark, moist, and richly supplied with blood—perfect “fertile soil” for melanocytes. The choroid alone holds nearly 90 % of them, so it is the commonest site. The ciliary body hides behind the iris; tumors there can grow large before anyone sees or feels trouble.Medscape

How doctors classify these eye melanomas

(A simple list is shown for clarity; detailed grading charts are much longer.)

Causes / risk factors

Below are everyday‑language paragraphs explaining each factor. Remember, most patients have several factors—or none that they know about—so no single item “causes” the cancer on its own.

1. Light‑coloured eyes (blue or green). Less melanin means less natural UV filter, so DNA in uveal melanocytes is slightly easier to damage.Mayo Clinic

2. White/Caucasian ancestry. Melanoma of any organ is commoner in fair‑skinned people; the eye shows the same pattern.Mayo Clinic

3. Older age (50 +). DNA errors pile up over decades, and immune “patrols” slow down, giving abnormal cells more time to grow.Mayo Clinic

4. Male sex. Hormonal or behavioural differences (more outdoor jobs, fewer eye checks) may raise risk slightly.

5. Chronic ultraviolet (UV) light exposure. Strong sunlight and tanning beds reach the eye through the cornea and lens. Animal and lab studies show UV can mutate ocular melanocytes, and population studies link high‑sun regions with more cases.PMC

6. Welding arcs and snow‑field glare. Intense artificial or reflected UV peaks add extra dose to the eye.

7. Ocular or oculo‑dermal melanocytosis. This birth‑mark‑like patch of extra pigment cells in eye and skin carries a lifetime melanoma risk up to 1 in 10.

8. Dysplastic (atypical) nevus syndrome. Families prone to odd skin moles often gather eye melanomas too, hinting at shared gene faults.

9. BAP1 tumour‑predisposition syndrome. Losing one copy of the BAP1 tumour‑suppressor gene (germline mutation) boosts odds of uveal melanoma to around 30 %.Myriad Genetics

10. Somatic GNAQ or GNA11 mutations. These “driver” changes switch on the same MAP‑kinase growth pathway seen in skin melanomas, setting the cell’s accelerator pedal down.

11. SF3B1 and EIF1AX mutations. These appear later in tumor life; SF3B1 links with medium risk, EIF1AX with low risk and better survival.Nature

12. Previous cutaneous melanoma. Some people make multiple melanomas in different organs, either from shared genes or shared UV behaviour.

13. Weakened immunity (HIV, transplant drugs). Fewer immune “checks” let abnormal pigment cells escape deletion.

14. Family history of uveal melanoma. About 1 %–6 % of patients have an affected relative; many of these clusters carry unrecognised BAP1 faults.PMC

15. Occupational chemical exposure. Small studies note more cases in farmers and petrochemical workers, but the data remain limited.

Symptoms

Many tumors stay silent until they are large, so routine eye exams are vital. When symptoms do appear they often include:

1. Blurred or reduced central vision. A growing lump distorts the retina or macula, so fine detail looks smudged.

2. Flashes (photopsia). The retina “fires” stray light signals when tugged or irritated by the underlying mass.Mayo Clinic

3. Floaters. Specks or cobwebs drift across vision if tiny bits of pigment or blood leak into the vitreous jelly.Mayo Clinic

4. Visual‑field loss. Side vision vanishes when the tumor blocks incoming light or damages nerve layers.

5. A dark spot on the iris or white of the eye. Some melanomas push pigment forward where it can be seen in daylight.

6. Change in pupil shape. A bulging mass presses the iris from behind, turning the round pupil oval or off‑centre.Mayo Clinic

7. Eye pain or redness. Tumor‑related inflammation or secondary glaucoma raises pressure and irritates nerves.

8. Sudden high pressure (acute glaucoma). A ciliary‑body mass can block drainage channels, causing headache, halos, and nausea.

9. Lens wobble or cataract. Tumor growth can nudge the lens out of place or cloud it, blurring vision further.Medscape

10. No symptom at all. Up to half of choroidal melanomas are discovered incidentally during routine dilated funduscopy—a strong case for regular eye checks after age 40.

Diagnostic tests

Below you will find plain‑speech descriptions of each test and why it is useful. Doctors rarely need all twenty for one patient, but the list shows the full toolkit.

A. Physical‑examination tools

1. Visual‑acuity chart. Reading rows of letters pinpoints any drop in central sharpness and sets a baseline for later comparison.

2. Pupil‑light reflex test. Swinging a torch from one eye to the other exposes a “relative afferent pupillary defect,” hinting at retinal or optic‑nerve damage.

3. Slit‑lamp biomicroscopy. A table‑mounted microscope plus a thin sheet of light lets the doctor scan the cornea, lens, iris, and anterior ciliary body for hidden masses.

4. Indirect ophthalmoscopy with scleral depression. Wearing a headlight and lens, the examiner views the whole choroid in 3‑D; gentle pressure flattens the eye wall so the far periphery comes into view.

B. Manual or bedside functional tests

5. Amsler grid. A small grid card reveals wavy or blank spots if the macula above a tumor is distorted.

6. Confrontation visual‑field test. Wiggling fingers in each quadrant quickly checks for scotomas (blind patches).

7. Tonometry (intra‑ocular pressure). A puff of air or tiny probe measures the eye’s internal pressure; a tumor can raise or occasionally lower it.

C. Laboratory / pathological investigations

8. Fine‑needle aspiration biopsy (FNAB). A hair‑thin needle draws a few tumor cells through the wall for microscope review; results confirm melanoma and feed gene tests.

9. Immunohistochemistry (HMB‑45, Melan‑A, SOX10). Stains light up melanoma proteins so pathologists can separate melanoma from pigmented lymphoma or metastasis.

10. Liver‑function panel (AST, ALT, ALP, bilirubin). Because the liver is the most common landing site for spread, baseline and follow‑up blood tests flag early trouble.

11. Serum lactate dehydrogenase (LDH). A general “tumor load” marker that can climb when metastases burst cells open.

D. Electro‑diagnostic tests

12. Electro‑retinography (ERG). Tiny corneal electrodes record the retina’s electrical waves after a flash; a deep tumor may dampen the signal.

13. Visual‑evoked potential (VEP). Scalp leads measure the brain’s response to stripes or flashes; slowed peaks hint at optic‑nerve compression.

14. Electro‑oculography (EOG). Tracks the standing voltage across the retina while eyes swing side‑to‑side; may fall if widespread retinal pigment damage accompanies the mass.

E. Imaging studies

15. Colour fundus photography. High‑resolution pictures document size, shape, and orange lipofuscin dots on the tumor surface—useful for “growing nevus or not?” follow‑up.

16. B‑scan ultrasonography. Sound waves form a cross‑section showing a solid, acoustic‑hollow dome or mushroom; thickness accuracy is ±0.2 mm.Retina Today

17. Ultrasound biomicroscopy (UBM). A 50‑MHz probe resolves fine detail in anterior tumors, ideal for ciliary‑body lesions that slit‑lamps cannot see.Retina Today

18. Optical coherence tomography (OCT). Near‑infra‑red light paints micron‑thin layers of retina and choroid; overlying drusen, sub‑retinal fluid, or retinal traction stand out.

19. Fluorescein and indocyanine‑green angiography. Dyes injected into a vein map leaky, double‑circulation vessels that are typical of melanoma and help rule out hemangioma.

20. Magnetic‑resonance imaging (MRI) of orbits and liver. MRI shows mushroom‑shaped, hyper‑intense (short T1) ocular masses and screens the liver for early spread without radiation—a standard baseline in many centres.American Academy of Ophthalmology

Non-pharmacological treatments

Below each therapy you’ll see Description → Purpose → How it may work (simplified). These are supportive measures that enhance quality of life and sometimes improve survival when paired with medical care.

A. Exercise-therapy approaches

• Brisk walking 30 min daily – builds cardio-fitness → lowers cancer-related fatigue by improving mitochondrial efficiency and reduces insulin spikes that may fuel tumour growth. American Cancer Society

• Resistance-band strength training twice weekly – maintains muscle → counters steroid-induced wasting, stimulates myokines that damp inflammation.

• Gentle yoga (Hatha) – combines stretching with deep breathing → eases anxiety, sleep trouble, and cortisol surges. ResearchGate

• Tai Chi – slow, balanced moves → boosts proprioception, reduces fall risk after radiotherapy.

• Aquatic therapy – buoyancy-supported exercises → safe when vision is reduced; improves joint range without eye strain.

• Stationary-bike intervals – low-impact cardio in controlled setting → keeps VO₂-max up during systemic therapy.

• Eye-positioning drills prescribed by the surgeon – seated head-upright routines → minimises sub-retinal fluid accumulation post-plaque therapy. New York Eye Cancer Center

B. Mind–body modalities

• Mindfulness-based stress reduction (MBSR) – 8-week programme → lowers sympathetic overdrive, steadies immune-cell ratios.

• Guided imagery sessions – daily audio tracks → recruits parasympathetic tone, reduces pain perception.

• Progressive muscle relaxation – sequenced tensing-release → drops blood pressure spikes that worsen optic-nerve perfusion.

• Breath-synchronised meditation (4-7-8 pattern) → eases insomnia common after steroid eye-drops.

• Music therapy – personalised playlists in infusion suite → distracts from adverse-event anxiety.

• Art journaling – expressive drawing of visual field changes → aids emotional processing and clinician communication.

• Cognitive-behavioural therapy (short-course) – identifies catastrophic thoughts → improves adherence to follow-up visits.

C. Educational self-management strategies

• Disease-specific teaching modules – booklet + videos → empowers patients to recognise subtle recurrence signs early.

• Symptom-tracking diaries – paper or app log → captures toxicity trends, triggers timely medication tweaks.

• Peer-support groups (online/face-to-face) → reduce isolation, share coping hacks.

• Tele-health coaching – regular nurse calls → nudges exercise, diet and appointment compliance.

• Nutrition counselling using ACS guidelines – personalised meal plans → corrects unintended weight-loss or gain. American Cancer Society

• Home vision-safety audits – occupational-therapist visit → prevents falls and eye injuries while vision is fluctuating.

---

Evidence-based drugs & biologics

*Doses are adult standards; clinicians adjust for organ function, body-size and comorbidities.

---

Dietary molecular supplements

Always clear supplements with an oncologist; high doses can interact with immunotherapy or surgery.

---

Regenerative / stem-cell-based drug strategies (research & early access)

1. Tumour-infiltrating lymphocyte (TIL) therapy – lifileucel: one-off IV infusion after lymphodepletion; functional T-cells expanded ex-vivo recognise melanoma antigens and can shrink liver mets.

2. gp100-redirected CAR-T cells: personalised autologous product under phase I study; aims to mirror tebentafusp without HLA restriction.

3. Dendritic-cell vaccine pulsed with gp100 & Melan-A peptides: subcutaneous prime-boost schedule; trains naïve T-cells.

4. iPSC-derived NK-cell infusions: off-the-shelf cytotoxic cells that survey residual disease.

5. Mesenchymal-stem-cell exosomes loaded with miR-34a: experimental liver-directed drops to silence MET oncogene.

6. Oncolytic virus-armed stem-cell carriers (HSV-T-VEC scaffold): stem cells home to liver deposits, release viral payload that lyses tumour cells.

All six remain investigational; dosing determined by trial protocol only.

---

Key surgical or procedure-based treatments

1. Plaque brachytherapy – a gold or steel disc holding I-125 or Ru-106 is stitched over the tumour for 3–7 days, delivering high-dose local radiation while sparing most retina; preserves vision in many medium tumours. EyeWiki

2. Proton-beam radiotherapy – cyclotron-generated particles aimed through custom collimators; ideal for tumours near the optic nerve; non-invasive and highly precise.

3. Partial lamellar sclerouvectomy (“local resection”) – surgeon removes tumour through a scleral window; benefits include pathologic confirmation and rapid resolution of fluid.

4. Endoresection via pars-plana vitrectomy – used when the overlying retina is detached; allows internal debulking plus adjuvant laser.

5. Enucleation – whole-eye removal for very large or painful eyes; eliminates tumour bulk and allows orbital implant placement.

---

Practical prevention strategies

1. Wear wrap-around UV-blocking sunglasses outdoors.

2. Avoid tanning beds and unshielded welding arcs.

3. Schedule annual dilated-eye exams after age 40 or sooner if high-risk.

4. Photograph large choroidal nevi and track changes.

5. Treat chronic uveitis promptly.

6. Maintain a healthy BMI and exercise per ACS targets.

7. Eat an antioxidant-rich diet (leafy greens, colourful berries).

8. Stop smoking – tobacco toxins dampen tumour immunity.

9. Limit heavy alcohol binges; alcohol can intensify retinal micro-bleeds.

10. Educate first-degree relatives about early signs and screening.

---

When should you see an eye-care or cancer specialist?

• Immediately if you notice sudden vision loss, a new curtain-like shadow, flashing lights, or eye pain.

• Within a week if a routine photo shows a pigmented spot that looks thicker or has orange pigment.

• Right away after any head or eye trauma if you already have a known choroidal nevus.

• Promptly if you develop unexplained weight loss, jaundice or right-upper-abdomen discomfort (possible liver spread).

Early referral to an ocular-oncology centre means more options and better survival odds. EyeWiki

---

Do’s and don’ts” (lifestyle checklist)

1. Do follow your treatment centre’s exact head-positioning advice after plaque surgery.

2. Do keep every six-month liver ultrasound appointment.

3. Do stay physically active – even light daily walks help.

4. Do use preservative-free artificial tears if radiotherapy dried your ocular surface.

5. Do keep a written medication & supplement list.

6. Don’t skip broad-brim hats in strong sun.

7. Don’t self-prescribe high-dose antioxidants during immunotherapy without approval.

8. Don’t ignore mild side-effects; early steroid eye-drops or immunosuppressants prevent vision loss.

9. Don’t drive at night until an optometrist confirms safe visual fields.

10. Don’t assume the other eye is immune; schedule surveillance for life.

---

Frequently Asked Questions (FAQs)

1. Is choroidal melanoma the same as skin melanoma?
No. They arise from the same pigment cell family but differ genetically and spread mostly to the liver, not skin or lymph nodes.

2. How common is it?
Roughly five new cases per million people per year – rare, but the most common eye cancer in adults. EyeWiki

3. Does it hurt?
Usually not until it’s large enough to raise pressure or bleed. That’s why routine checks matter.

4. Can laser alone cure it?
Today laser (trans-pupillary thermotherapy or photocoagulation) is used only as an adjunct in small residuals after radiation.

5. Will I lose my eye?
Eye-saving plaque brachytherapy or proton beam therapy control many tumours; enucleation is reserved for advanced or painful cases.

6. What is my survival outlook?
Small tumours caught early have 5-year survival > 95 %. Metastatic disease lowers survival, but tebentafusp now extends life by roughly 6–7 months compared with older options. U.S. Food and Drug Administration

7. Why does it favour the liver?
Melanoma cells circulate, and the liver’s “filter” receives most eye-drainage blood, providing a hospitable micro-environment.

8. Do sunglasses really help?
Yes – lab studies show UV-A can damage choroidal DNA; epidemiology links cumulative exposure to greater risk.

9. Are children affected?
Paediatric cases are extremely rare; most are in adults over 50.

10. Can I fly after plaque therapy?
Most patients may fly after the plaque is removed and the surgeon clears them; cabin pressure does not harm the treated eye.

11. Is genetic testing useful?
Gene-expression profile strongly predicts metastatic risk and guides follow-up intensity.

12. Does diet shrink a tumour?
Diet alone cannot destroy melanoma cells, but balanced nutrition supports immunity and treatment tolerance.

13. Are stem-cell treatments available outside trials?
Not yet. TIL therapy is FDA-approved for skin melanoma, but eye-melanoma-specific protocols are still in clinical trials.

14. How often will I need liver scans?
Typically every 6 months for 5 years, then yearly if no spread is found, though high-risk Class 2 tumours may need quarterly imaging.

15. Can the cancer come back in the treated eye?
Yes, local recurrence occurs in 5–10 % of plaque-treated eyes; lifelong follow-up is non-negotiable.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 16, 2025.